- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06333808
Studie zum Vergleich von Bictegravir/Lenacapavir mit der aktuellen Therapie bei Menschen mit HIV-1, die erfolgreich mit Biktarvy behandelt werden (ARTISTRY-2)
Doppelblinde, multizentrische, randomisierte, aktiv kontrollierte Phase-3-Studie zur Bewertung der Sicherheit und Wirksamkeit von Bictegravir/Lenacapavir im Vergleich zu Biktarvy® (Bictegravir/Emtricitabin/Tenofoviralafenamid) bei virologisch unterdrückten Menschen mit HIV-1
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH) who are successfully treated with B/F/TAF (virologically suppressed).
The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) FDC tablets versus continuing on B/F/TAF (50/200/25 mg) FDC tablets in virologically suppressed PWH.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Buenos Aires, Argentinien, C1141ACG
- Helios Salud S.A.
-
Buenos Aires, Argentinien, C1202ABB
- Fundacion Huesped
-
Santa Fe, Argentinien, S2000PBJ,
- Instituto CAICI SRL
-
-
-
-
New South Wales
-
Darlinghurst, New South Wales, Australien, 2011
- Taylor Square Private Clinic
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Alfred Hospital(Alfred Health)
-
South Yarra, Victoria, Australien, 3141
- Prahran Market Clinic
-
-
-
-
-
Aachen, Deutschland, 52062
- Praxis Dr. Knechten
-
Berlin, Deutschland, 10117
- Novopraxis Berlin
-
Cologne, Deutschland, 50668
- Praxis am Ebertplatz
-
Frankfurt, Deutschland, 60590
- Universitätsklinikum Frankfurt
-
Hamburg, Deutschland, 20246
- Universitätsklinikum Hamburg Eppendorf
-
Munich, Deutschland, 80336
- LMU Klinikum der Universität
-
München, Deutschland, 81675
- Klinikum rechts der Isar der Technischen Universitaet Muenchen
-
-
-
-
-
Santo Domingo, Dominikanische Republik
- Instituto Dominicano de Estudios Virologicos - IDEV
-
-
-
-
-
Brescia, Italien, 25123
- ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia - INCIPIT - PIN
-
Foggia, Italien, 71122
- Azienda Ospedaliero Universitaria Ospedali Riuniti (Policlinico di Foggia)
-
Milan, Italien, 20127
- IRCCS Ospedale San Raffaele
-
Monza, Italien, 20090
- Fondazione IRCCS San Gerardo dei Tintori - ASST di Monza - A. O. San Gerardo
-
Pavia, Italien, 27100
- Fondazione IRCCS Policlinico San Matteo di Pavia
-
Roma, Italien, 00168
- Fondazione Policlinico Universitario A Gemelli-Rome
-
Roma, Italien, 00149
- Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS
-
-
-
-
-
Aichi, Japan, 460-0001
- National Hospital Organization Nagoya Medical Center
-
Osaka, Japan, 540-0006
- National Hospital Organization Osaka National Hospital
-
Tokyo, Japan, 162-0052
- Center Hospital of the National Center for Global Health and Medicine
-
-
-
-
-
Decarie Montreal, Kanada, H4A 3J1
- Chronic Viral Illness Service/McGill University Health Centre (MUHC)
-
Montreal, Kanada, H2L 4P9
- Clinique Médicale l'Actuel
-
Ottawa, Kanada, K1H 8L6
- The Ottawa Hospital - General Campus
-
Regina, Kanada, S4P 0W5
- Regina General Hospital
-
Vancouver, Kanada, V6Z1Y6
- St. Paul's Hospital, John Ruedy Clinic-Immunodeficiency Clinic (JRC-IDC)
-
Victoria, Kanada, V8W 1M8
- Cool Aid Community Health Centre
-
-
-
-
-
Mexico City, Mexiko, 6170
- ProcliniQ Investigacion Clinica Toriello Guerra, Tlalpan
-
Mérida, Mexiko, 97070
- Unidad de Atencion Medica e Investigacion en Salud
-
-
-
-
PR
-
San Juan, PR, Puerto Rico, 00935
- Proyecto ACTU
-
San Juan, PR, Puerto Rico, 00909
- HOPE Clinical Research
-
-
-
-
-
Badalona Barcelona, Spanien, 8916
- Hospital Universitario Germans Trias i Pujol
-
Barcelona, Spanien, 08036
- Hospital Clinic de Barcelona
-
Madrid, Spanien, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spanien, 28046
- Hospital Universitario La Paz - PPDS
-
Seville, Spanien, 4103
- Hospital Universitario Virgen del Rocio - PPDS
-
Valencia, Spanien, 46014
- Consorcio Hospital General Universitario de Valencia
-
-
-
-
-
Daegu, Südkorea, 41944
- Kyungpook National University Hospital
-
Seoul, Südkorea, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Südkorea, *04564
- National Medical Center
-
Seoul, Südkorea, 137-701
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
-
-
-
-
Kaohsiung City, Taiwan, 81362
- Kaohsiung Veterans General Hospital
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
Taoyuan City, Taiwan, 33004
- Taoyuan General Hospital, Ministry of Health and Welfare
-
-
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85015
- Pueblo Family Physicians
-
-
California
-
Berkeley, California, Vereinigte Staaten, 48072
- Be Well Medical Center
-
Beverly Hills, California, Vereinigte Staaten, 90211
- Pacific Oaks Medical Group
-
Los Angeles, California, Vereinigte Staaten, 90036
- Ruane Clinical Research Group Inc.
-
Oakland, California, Vereinigte Staaten, 94609
- Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
-
Palm Springs, California, Vereinigte Staaten, 92262
- BIOS Clinical Research
-
San Diego, California, Vereinigte Staaten, 92103
- UCSD Anti Viral Research Centre (AVRC)
-
Torrance, California, Vereinigte Staaten, 90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
West Hollywood, California, Vereinigte Staaten, 90046
- Mills Clinical Research
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80204
- Public Health Institute at Denver Health
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06510
- Yale University School of Medicine (study visits)
-
-
Florida
-
DeLand, Florida, Vereinigte Staaten, 32720
- Midland Florida Infectious Diseases Specialists, PL - Orange City
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33308
- Therafirst Medical Center
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33316
- CAN Community Health
-
Ft. Pierce, Florida, Vereinigte Staaten, 34982
- Midway Immunology and Research Center
-
Miami, Florida, Vereinigte Staaten, 33133
- AIDS Healthcare Foundation - The Kinder Medical Group
-
Miami, Florida, Vereinigte Staaten, 33136
- Schiff Center for liver Diseases/University of Miami
-
Miami Lakes, Florida, Vereinigte Staaten, 33016
- Floridian Clinical Research
-
Orlando, Florida, Vereinigte Staaten, 32803
- Orlando Immunology Center
-
Orlando, Florida, Vereinigte Staaten, 32806
- Bliss Healthcare
-
Pensacola, Florida, Vereinigte Staaten, 32503
- AHF Pensacola
-
Sarasota, Florida, Vereinigte Staaten, 34237
- CAN community Health
-
West Palm Beach, Florida, Vereinigte Staaten, 33407
- Triple O Research Institute, P.A.
-
-
Georgia
-
Decatur, Georgia, Vereinigte Staaten, 30033
- Infectious Disease Specialists of Atlanta
-
Macon, Georgia, Vereinigte Staaten, 31201
- Mercer University, Department of Internal Medicine
-
-
Massachusetts
-
Springfield, Massachusetts, Vereinigte Staaten, 01105
- Claudia T Martorell MD LLC dba The Research Institute
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Henry Ford Health
-
-
Missouri
-
Kansas City, Missouri, Vereinigte Staaten, 64111
- KC Care health Center
-
St Louis, Missouri, Vereinigte Staaten, 63139
- Southampton Community Healthcare, Inc.
-
-
New Jersey
-
Hillsborough, New Jersey, Vereinigte Staaten, 08844
- ID Care, LLC
-
Newark, New Jersey, Vereinigte Staaten, 07102
- Saint Michael's Medical Center
-
Newark, New Jersey, Vereinigte Staaten, 07103
- New Jersey Medical School - Clinical Research Center
-
Somers Point, New Jersey, Vereinigte Staaten, 08244
- South Jersey Infectious Disease
-
-
New Mexico
-
Santa Fe, New Mexico, Vereinigte Staaten, 87505
- AXCES Research Group, LLC
-
-
New York
-
Flushing, New York, Vereinigte Staaten, 11355
- New York-Presbyterian Queens
-
The Bronx, New York, Vereinigte Staaten, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Greenville, North Carolina, Vereinigte Staaten, 27858
- The Brody School of Medicine at East Carolina University , ECU Adult Specialty Care
-
Huntersville, North Carolina, Vereinigte Staaten, 28078
- Rosedale Health and Wellness
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Philadelphia FIGHT Community Health Centers
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Medical University of South Carolina (MUSC) Research Nexus
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78705
- Central Texas Clinical Research
-
Bellaire, Texas, Vereinigte Staaten, 77401
- St Hope Foundation, Inc.
-
Dallas, Texas, Vereinigte Staaten, 75208
- AIDS Arms, Inc. DBA Prism Health North Texas
-
Dallas, Texas, Vereinigte Staaten, 75246
- North Texas Infectious Diseases Consultants, PA
-
El Paso, Texas, Vereinigte Staaten, 79902
- AXCES Research Group, LLC
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Texas Centers for Infectious Disease Associates
-
Houston, Texas, Vereinigte Staaten, 77098
- The Crofoot research Center, INC.
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84102
- AXCES Research Group, LLC
-
-
Virginia
-
Annandale, Virginia, Vereinigte Staaten, 22003
- Clinical Alliance For Research & Education - Infectious Diseases. LLC (CARE-ID)
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- Peter Shalit MD
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Community Health care
-
-
-
-
-
Liverpool, Vereinigtes Königreich, L7 8XP
- Liverpool University Hospitals NHS Foundation Trust, Royal Liverpool Hospital
-
London, Vereinigtes Königreich, WC1E 6JB
- Mortimer Market Centre
-
London, Vereinigtes Königreich, SE5 9RS
- King's College Hospital, Weston Education Centre
-
London, Vereinigtes Königreich, SW109NH
- Chelsea and Westminster Hospital NHS Foundation Trust, St Stephen's Centre, Chelsea and Westminster Hospital
-
London, Vereinigtes Königreich, W2 1NY
- St Mary's Hospital - PPDS
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
- Currently receiving B/F/TAF for at least 6 months prior to screening.
- If plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) measurements in the last 6 months prior to screening are available, all levels must be < 50 copies/mL.
- At least one documented HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL.
- Plasma HIV-1 RNA levels < 50 copies/mL at screening.
- No documented or suspected resistance to BIC (including integrase strand-transfer inhibitor resistant (INSTI-R) mutations T66A/I/K, E92G/Q, G118R, F121Y, Y143C/H/R, S147G, Q148H/K/R, N155H/S, or R263K in the integrase gene).
- No documented or suspected resistance to tenofovir alafenamide (TAF) (TAF; mutations K65R, K65N, K70E, Q151M or T69 insertion, or ≥ 3 of the following thymidine analog mutations [M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R] in the reverse transcriptase gene).
- Estimated glomerular filtration rate ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance.
Key Exclusion Criteria:
-
Positive serum pregnancy test or pregnant at screening or a positive pregnancy test prior to Day 1 randomization.
-
Breastfeeding (nursing).
-
Prior use of, or exposure to, LEN.
-
Active, serious infections (other than HIV-1) requiring parenteral therapy < 30 days prior to randomization.
-
Active tuberculosis infection.
-
Acute hepatitis < 30 days before randomization.
-
Chronic hepatitis B virus (HBV) infection, as determined by either:
- Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit.
- Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit.
-
Known hypersensitivity to the study drug, its metabolites, or any formulation excipient.
-
History of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).
-
Abnormal electrocardiogram (ECG) at the screening visit that is clinically significant as determined by the investigator.
-
Active malignancy requiring acute systemic therapy.
-
Any of the following laboratory values at screening:
- Alanine aminotransferase > 5 × upper limit of normal (ULN).
- Direct bilirubin > 1.5 × ULN.
- Platelets < 50,000/mm^3.
- Hemoglobin < 8.0 g/dL.
-
Requirement for ongoing therapy with or prior use of any prohibited medications listed in the protocol.
-
Participation or planned participation in any other clinical study (including observational studies) without prior approval from the sponsor.
-
Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg
Participants will switch from bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed-dose combination (FDC) tablets to bictegravir/lenacapavir (BIC/LEN) 75/50 mg FDC tablets + placebo-to-match (PTM) B/F/TAF tablets, administered orally, once daily up to 48 weeks. Participants will also receive a 2-day oral pharmacokinetic (PK) loading dose of LEN 600 mg on Days 1 and 2, in addition to the daily doses of BIC/LEN 75/50 mg and PTM B/F/TAF tablets starting on Day 1. At the end of blinded treatment (EBT) participants will enter the open label (OL) phase and continue to receive BIC/LEN 75 mg/50 mg FDC tablets through at least 48 weeks in the OL phase. At the OL Week 48, participants will be given an option to continue to receive BIC/LEN FDC tablets. |
Tablets administered orally without regard to food
Andere Namen:
Tablets administered orally without regard to food
Andere Namen:
Tablets administered orally without regard to food |
|
Aktiver Komparator: Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg
Participants will continue with their B/F/TAF 50/200/25 mg tablets and start PTM BIC/LEN tablets on Day 1 administered orally, once daily up to 48 weeks. Participants will receive PTM oral LEN PK loading tablets for 2 days (2 PTM LEN tablets on Day 1 and on Day 2). Participants who complete the EBT will be given an option to enter the OL phase to receive BIC/LEN FDC tablets. |
Tablets administered orally without regard to food
Andere Namen:
Tablets administered orally without regard to food Tablets administered orally without regard to food |
|
Experimental: Open-label Phase: BIC/LEN 75/50mg
Participants from Treatment Group 1 will receive BIC/LEN FDC tablets through at least OL Week 48. At the OL Week 48 visit, participants from Treatment Group 1 will be given the option to continue to receive BIC/LEN FDC tablets. Participants in Treatment Group 2 who complete the EBT visit will be given the option to enter the OL phase to receive BIC/LEN FDC tablets. Participants from Treatment Group 2 who enter the OL phase will also receive a 2-day oral loading dose of LEN 600 mg (2 × 300 mg LEN on Day 1 and on Day 2). All participants who enter the OL phase may continue to receive BIC/LEN FDC tablets daily until study drug is available or until Gilead Sciences (Gilead) elects to discontinue the study. |
Tablets administered orally without regard to food
Andere Namen:
Tablets administered orally without regard to food
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Zeitfenster: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and participants who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than adverse event (AE), death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window was between Days 295 and 378 (inclusively). Percentages were rounded off. |
Week 48
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm
Zeitfenster: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off. |
Week 48
|
|
Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 48
Zeitfenster: Baseline, Week 48
|
Baseline, Week 48
|
|
|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 48
Zeitfenster: First dose date up to Week 48
|
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC/LEN FDC, Treatment Group 1) or 30 days (for B/F/TAF, Treatment Group 2) or any AE leading to study drug discontinuation. Percentages were rounded off. |
First dose date up to Week 48
|
|
Treatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-Defined Snapshot Algorithm
Zeitfenster: Week 96
|
Week 96
|
|
|
Treatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by US FDA-Defined Snapshot Algorithm
Zeitfenster: Week 96
|
Week 96
|
|
|
Treatment Group 1: Change From Baseline in CD4 Cell Count at Week 96
Zeitfenster: Week 96
|
Week 96
|
|
|
Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 96
Zeitfenster: First dose date up to Week 96
|
First dose date up to Week 96
|
|
|
Treatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-Defined Snapshot Algorithm
Zeitfenster: Week 144
|
Week 144
|
|
|
Treatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by US FDA-Defined Snapshot Algorithm
Zeitfenster: Week 144
|
Week 144
|
|
|
Treatment Group 1: Change From Baseline in CD4 Cell Count at Week 144
Zeitfenster: Week 144
|
Week 144
|
|
|
Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 144
Zeitfenster: First dose date up to Week 144
|
First dose date up to Week 144
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Gilead Study Director, Gilead Sciences
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Arora P, Hindman JT, West S, Ling J, Palaparthy R, Marathe DD. The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study. Antimicrob Agents Chemother. 2026 Jan 7;70(1):e0078125. doi: 10.1128/aac.00781-25. Epub 2025 Nov 28.
- Meissner EG, Ramgopal M, Ruane PJ, Sanchez W, Crofoot G, Routy JP, Brinson C, DeJesus E, Martorell CT, Tellez M, Yokomaku Y, O'Reilly M, Lupo S, Schellberg S, Lezama-Mora JI, Chin B, Aizen K, D'Antoni ML, Huang H, Mponponsuo K, Montezuma-Rusca JM, Sklar P, Rhee M, Hung CC; ARTISTRY-2 Study Group. Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet HIV. 2026 Aug;13(8):e538-e547. doi: 10.1016/S2352-3018(26)00078-0. Epub 2026 May 6.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- GS-US-621-6290
- 2023-510022-33 (Andere Kennung: European Medicines Agency)
- jRCT2051240046 (Registrierungskennung: Japan Registry)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .